Navigation Links
Novelos Therapeutics and MUSC Present Two Posters at AACR 2007,Annual Meeting

NEWTON, Mass.--(BUSINESS WIRE)--Apr 16, 2007 - Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the company, in collaboration with Dr. Kenneth Tew and Dr. Danyelle Townsend of the Medical University of South Carolina (MUSC), is making two poster presentations at the ongoing American Association for Cancer Research annual meeting. These presentations will highlight in vivo and in vitro findings with NOV-002, which is currently in a pivotal Phase 3 trial for non-small cell lung cancer and Phase 2 trials for other oncology indications. The posters are available at www.novelos.com 'Our Products', 'NOV-002' section.

"As clinical development of NOV-002 progresses, we continue to add to our understanding of its molecular and cellular mechanisms of action as they may relate to therapeutic activity," said Christopher Pazoles, Ph.D., Vice President of Research & Development of Novelos. "Our ongoing and broad-ranging research collaboration with Drs. Tew and Townsend at MUSC is an important part of that effort."

About Novelos Therapeutics, Inc.

Novelos Therapeutics, Inc. is a biopharmaceutical company commercializing oxidized glutathione-based compounds for the treatment of cancer and hepatitis. NOV-002, the lead compound currently in Phase 3 development for lung cancer under a SPA and Fast Track, acts together with chemotherapy as a chemoprotectant and an immunomodulator. NOV-002 is also in Phase 2 development for chemotherapy-resistant ovarian cancer and early-stage breast cancer, and is in addition being developed for acute radiation injury. NOV-205 acts as a hepatoprotective agent with immunomodulating and anti-inflammatory properties. NOV-205 is in Phase 1b development for chronic hepatitis C non-responders. Both compounds have completed clinical trials in humans and have been approved
'"/>




Page: 1 2

Related medicine technology :

1. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
10. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
11. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
Post Your Comments:
(Date:7/11/2014)... July 11, 2014 Neurelis, Inc. ("Neurelis") today ... end the option held by Biotie to purchase Neurelis, ... of NRL-1 (intranasal diazepam) for pediatric and adult epilepsy ... the past year, Biotie has advanced the development program ... the pivotal clinical work required for NDA submission to ...
(Date:7/10/2014)... 2014  The U.S. Department of Health and Human ... Hospitals (UH) Case Medical Center Seidman Cancer Center totaling ... at improving care for patients with complex cancer. ... test a unique model developed at UH to enhance ... comorbidities, or demonstrated need for high health care utilization.  ...
(Date:7/10/2014)... INC. (NYSE: RMD ) today announced that it ... 30, 2014 results on Thursday, July 31, 2014, after the ... ResMed,s results will be issued after 1:00 p.m. US Pacific ... operating results and future outlook. The earnings call ... and the live webcast of the call can be accessed ...
Breaking Medicine Technology:Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2
... Clinical Program Leverages Quark,s RNAi Technology, FREMONT, ... pharmaceutical company discovering and developing novel,RNA interference (RNAi)-based ... patient dosing in a Phase II trial,evaluating, ... (DME)., PF-4523655 is a novel siRNA drug ...
... Does Not Mean the End of Anti-Amyloid,Therapies -, ... studies,of potential new treatments for Alzheimer,s - even ... field,s knowledge and point scientists,toward advances in therapies ... the 2008 Alzheimer,s Association International Conference,on Alzheimer,s Disease ...
Cached Medicine Technology:Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema 2Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema 3Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema 4Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation 2Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation 3Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation 4Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation 5Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation 6Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation 7Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation 8Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation 9Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation 10Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation 11
(Date:7/12/2014)... prom shopping reaching its final days, VogueQueen.com, a renowned ... its new and trendy apparels. Recently, the company has ... online shop. Additionally, it is now providing huge discounts ... to the company’s sales manager, the promotion will come ... He says, “Now, worldwide clients can order cheap ...
(Date:7/12/2014)... PA (PRWEB) July 12, 2014 Doylestown ... covering a variety of men’s health questions. Paddock ... specific to men, why women live longer than men, ... Men's Health Made Simple featured on Doylestown ... get a hernia at any age. If you notice ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 A recent article ... provides a trio of suggestions for those seeking cosmetic ... days are rapidly approaching and the heat begins to enliven ... to their summer clothing, realizing that they didn’t work out ... , This can cause a sudden surge of people eager ...
(Date:7/12/2014)... July 12, 2014 Floor-grade ... of 4.1 out of 5. This above-average score ... been underpinning buyer negotiation power over the three ... Anna Son, “during the period, surging demand for ... associated with new product development, have placed upward ...
(Date:7/11/2014)... MagicQuinceaneraDresses.com, the popular online supplier of special occasion gowns, ... dresses . The company’s new items are specially designed ... a large amount of money. They are all available ... company’s online shop has become a one stop platform ... addition to exquisite Quinceanera dresses, it also offers great ...
Breaking Medicine News(10 mins):Health News:VogueQueen.com Updates Its Summer Collection With New And Trendy Evening Dresses 2Health News:Ivyland Medical Center’s Dr. Brad Paddock Offers Tips for Men’s Health 2Health News:Best Summer Cosmetic Surgeries Revealed in Article By Seattle Plastic Surgeon 2Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 4Health News:Cheap Quinceanera Dresses Now Available At MagicQuinceaneraDresses.com 2
... sexual intercourse for couples lasts from 3 to 13 ... hours of sexual activity, according to a survey of ... Eric Corty and Jenay Guardiani conducted a survey of ... and Research, which include psychologists, physicians, social workers, marriage/family ...
... Will Arnett, Matthew Broderick, Steve Carell, Stephen, Colbert, ... James,Conan O,Brien, Rosie O,Donnell, Amy Poehler, Adam Sandler, Sarah ... Insult Comic Dog And Many More To Be Announced, ... today that,Kelsey Grammer, Ben Stiller, Grammy Award-winning band Maroon ...
... Work in primates points to possible weapon against human ... News) -- Researchers have successfully tested several Ebola vaccines ... first human vaccine for one of the world,s deadliest ... cannot be overlooked. We are seeing more and more ...
... French . , Montreal, March 31, 2008 ... novel gene responsible for a significant fraction of ALS (sporadic ... Lou Gehrigs disease, an incurable neuromuscular disorder that affects motor ... five years. , Published in the current online edition of ...
... March 31 The Epilepsy,Foundation,s quick reaction to a ... raises awareness of the need for Web security for ... and those who,use its online forums for help, support, ... posted rapidly flashing images to cause,serious injury and harm. ...
... --- University of Florida chemists are the first to use ... diseases -- without any previous knowledge of what these microscopic ... in the online edition of the Journal of Proteome Research, ... improved treatment of some types of cancer as well as ...
Cached Medicine News:Health News:Good sexual intercourse lasts minutes, not hours, therapists say 2Health News:Kelsey Grammer, Ben Stiller, Maroon 5 and The Roots Added to COMEDY CENTRAL's(R) Live On-air Charity Special 'Night of Too Many Stars: An Overbooked Concert for Autism Education' Hosted by Jon Stewart on Sunday April 13, at 8 p.m. ET 2Health News:Researchers Successfully Test Ebola Vaccines 2Health News:Researchers identify a gene responsible for cases of Lou Gehrig's disease 2Health News:Epilepsy Foundation Takes Action Against Hackers 2Health News:Scientists: New technique identifies molecular 'biomarkers' for disease 2Health News:Scientists: New technique identifies molecular 'biomarkers' for disease 3